drugset / Trial / NCT02925793

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793 ↗

Phase 2 Completed 327 enrolled DS Biopharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients with mild to moderate Atopic Dermatitis (AD).

Timeline

Start
2016-12
Primary completion
2018-07
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DIHOMO-GAMMA-LINOLENIC ACID Small molecule 1 % Topical
Subject DIHOMO-GAMMA-LINOLENIC ACID Small molecule 5 % Topical

Indications